Corporate Profile

Daxor Corporation (NYSE: DXR) is an innovative medical instrumentation and biotechnology company focused on blood volume measurement.  We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms.  The BVA technology has the potential to improve hospital performance metrics in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved patient outcomes. Our mission is to partner with clinicians to incorporate BVA technology into standard clinical practice and improve the quality of life for patients.

Daxor Corporation
350 Fifth Ave, Suite 4740
New York, NY 10118
Investor Relations
Bret Shapiro
377 Oak Street
Garden City, NY 11530

 Stock Performance

 Management Team

Michael Feldschuh – CEO & President
Jonathan Feldschuh – Chief Scientific Officer
Kathryn A. Kornafel – VP Marketing & Commercial Development
Robert Michel – Chief Financial Officer
Jean Oertel – VP Commercialization & Customer Experience
Soren Thompson – VP Business Development

 Board of Directors

Michael Feldschuh – Director
Henry D. Cremisi, MD, FACP – Director
Jonathan Feldschuh – Chief Scientific Officer
Edward S. Feuer – Director
Joy Goudie, Esq. – Director
James A. Lombard – Director

 Recent Headlines